The updated presentation shows improving operational metrics (20% revenue growth, 76% gross margins) and a cash runway through Q2 2027. Monitor upcoming milestones including FDA 510(k) submission for pediatric label expansion (Q4 2026) and Clarity PRIME commercial launch (H2 2027) for potential catalysts.
Price Chart
Executive Summary
Nuwellis, Inc. filed an 8-K on August 25, 2026, to furnish an updated corporate investor presentation (Exhibit 99.1). The presentation highlights 1H26 revenue growth of 20% year-over-year and a significant improvement in Q2 2026 gross margins to 76% from 56% in the prior-year period. The filing is a routine business update with no material new financial disclosures beyond the furnished presentation.
Key Facts
- 1H26 revenue growth of 20% over prior-year period.
- Q2 2026 gross margins improved to 76% compared to 56% in Q2 2025.
- Company posted an updated corporate presentation to its website on August 25, 2026.
- Cash runway through Q2 2027 to implement near-term growth initiatives.
- Company has ~135 active hospital accounts, including leading U.S. academic hospitals.
- Pediatric patients represent 50% of revenues.
Financial Impact
1H26 revenue grew 20% YoY; Q2 2026 gross margins expanded to 76% from 56% in Q2 2025.
Risk Factors
- Micro-cap with $4M market cap and high volatility.
- Forward-looking statements in the presentation are subject to risks including ability to raise capital and execute commercial strategy.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-034367 |
| Document: 0001140361-26-034367-index.html | 0001140361-26-034367 |
| Document: 0001140361-26-034367.txt | 0001140361-26-034367 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $0.3221 | awaiting T+20 | — | $3.07 (+851.69%) |
Sep 18, 2026 5w ago | SC 13G/A | $0.8700 $0.5600 | ▼ −35.63% | ▼ −34.72% | $3.07 (+252.34%) |
Sep 17, 2026 5w ago | Press Release | $1.09 $0.5532 | ▲ +49.25% | ▲ +50.45% | $3.07 (−181.23%) |
Aug 27, 2026 8w ago | EFFECT | $0.9900 $0.7915 | ▲ +20.05% | ▲ +19.95% | $3.07 (−209.64%) |
Aug 25, 2026 8w ago | 8-K | $1.01 $0.8700 | ▼ −13.86% | ▼ −15.06% | $3.07 (+203.50%) |
Aug 13, 2026 10w ago | Press Release | $1.30 $0.7740 | ▲ +40.46% | ▲ +38.71% | $3.07 (−135.80%) |
Aug 3, 2026 12w ago | 424B5 | $14.49 $7.13 | ▲ +50.78% | ▲ +52.01% | $3.07 (+78.84%) |
Jul 31, 2026 12w ago | Press Release | $1.74 $0.8889 | ▲ +48.91% | ▲ +51.90% | $3.07 (−76.17%) |
Jun 16, 2026 18w ago | Press Release | $0.1350 $0.0840 | ▼ −37.78% | ▼ −37.83% | $3.07 (+2170.67%) |
Jun 10, 2026 19w ago | 8-K | $0.1520 $0.0869 | ▲ +42.86% | ▲ +46.93% | $3.07 (−1916.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers